Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-Generation
- PMID: 26880570
- PMCID: PMC6490771
- DOI: 10.1002/clc.22512
Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-Generation
Abstract
There is an apparent benefit with extension of dual antiplatelet therapy (DAPT) beyond 1 year after implantation of drug-eluting stents (DES). Assessment by a Double Randomization of a Conventional Antiplatelet Strategy vs a Monitoring-Guided Strategy for Drug-Eluting Stent Implantation, and of Treatment Interruption vs Continuation One Year After Stenting (ARCTIC)-Generation assessed whether there is a difference of outcome between first- vs second-generation DES and if there is an interaction with DAPT duration in the ARCTIC-Interruption study. ARCTIC-Interruption randomly allocated 1259 patients 1 year after stent implantation to a strategy of interruption of DAPT (n = 624), in which aspirin antiplatelet treatment only was maintained, or DAPT continuation (n = 635) for 6 to 18 additional months. The primary endpoint was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization. A total of 520 and 722 patients received a first- and a second-generation DES, respectively. After a median follow-up of 17 months (interquartile range, 15-18 months) after randomization, the primary endpoint occurred in 32 (6.2%) and 19 (2.6%) patients with first- and second-generation DES, respectively (hazard ratio: 2.31, 95% confidence interval: 1.31-4.07, P = 0.004). This was observed irrespective of the strategy of interruption or continuation of DAPT and timing of study recruitment. Major bleeding events occurred in 4 (0.8%) and 3 patients (0.4%) with first- and second-generation DES, respectively (hazard ratio: 1.79, 95% confidence interval: 0.40-8.02, P = 0.44). Results did not change after multiple adjustments for potential confounding variables. ARCTIC-Generation showed worse clinical outcome with first- vs second-generation DES, a difference that appeared to persist even with prolonged DAPT.
© 2016 Wiley Periodicals, Inc.
Figures
References
-
- Garratt KN, Weaver WD, Jenkins RG, et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel‐eluting coronary stent placement. Circulation. 2015;131:62–73. - PubMed
-
- Stone GW, Rizvi A, Newman W, et al; SPIRIT IV Investigators . Everolimus‐eluting versus paclitaxel‐eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663–1674. - PubMed
-
- Stefanini GG, Baber U, Windecker S, et al. Safety and efficacy of drug‐eluting stents in women: a patient‐level pooled analysis of randomised trials [published correction appears in Lancet. 2013;382:1878]. Lancet. 2013;382:1879–1888. - PubMed
-
- Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug‐eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR‐TEST 3, ISAR‐TEST 4, and LEADERS randomized trials. Eur Heart J. 2012;33:1214–1222. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical